• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Alkermes plc

    2/13/25 4:36:05 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001730048
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Alkermes plc.
    SEC File Number
    001-35299
    Address of Issuer
    CONNAUGHT HOUSE
    1 BURLINGTON ROAD
    DUBLIN 4
    IRELAND
    00000
    Phone
    00-353-1-772-8000
    Name of Person for Whose Account the Securities are To Be Sold
    Hopkinson Craig C.
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Ordinary shares
    Merrill Lynch
    225 Liberty St
    Floor 37
    New York � NY � 10281
    1444195130694.1516261406702/13/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Ordinary shares02/13/2025Exercise of employee stock optionsAlkermes plc.Checkbox not checked14441902/13/2025Broker assisted cashless exercise

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Craig Hopkinson
    CONNAUGHT HOUSE
    1 BURLINGTON ROAD
    DUBLIN 4 � L2 � 00000
    Ordinary shares01/30/20251009183234380.13
    Craig Hopkinson
    CONNAUGHT HOUSE
    1 BURLINGTON ROAD
    DUBLIN 4 � L2 � 00000
    Ordinary shares12/09/2024611511961403.62
    Craig Hopkinson
    CONNAUGHT HOUSE
    1 BURLINGTON ROAD
    DUBLIN 4 � L2 � 00000
    Ordinary shares12/05/20249221290461.50
    Craig Hopkinson
    CONNAUGHT HOUSE
    1 BURLINGTON ROAD
    DUBLIN 4 � L2 � 00000
    Ordinary shares12/04/202414349441550.16
    Craig Hopkinson
    CONNAUGHT HOUSE
    1 BURLINGTON ROAD
    DUBLIN 4 � L2 � 00000
    Ordinary shares02/12/20252049216718276.17

    144: Remarks and Signature

    Remarks
    Date of Notice
    02/13/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    12/14/2023

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Craig Hopkinson

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ALKS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    6/17/2025$42.00Neutral → Buy
    UBS
    5/28/2025$45.00Buy
    Needham
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    3/4/2025$21.00 → $38.00Sell → Neutral
    UBS
    2/11/2025$40.00Buy
    Deutsche Bank
    11/5/2024$25.00 → $36.00Hold → Buy
    Stifel
    6/17/2024$34.00Buy
    TD Cowen
    3/19/2024$37.00Outperform
    Robert W. Baird
    More analyst ratings

    $ALKS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

      DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of c

      6/2/25 4:00:00 PM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences

      – Multiple Subgroup Analyses Presented From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan), Including Data on Lipid and Glycemic Profiles – DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the presentation of accepted research at key scientific conferences this spring, including presentations largely related to its psychiatry products LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil). Several of these meetings coincided with Mental Health Awareness Month in May, an important moment to raise awareness about mental health conditions, support the millions of people living with these complex diseases, and acknowledge the c

      6/2/25 7:00:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alkermes to Present New Research Related to ALKS 2680 at SLEEP 2025

      – Company to Present Eight Posters and Two Oral Presentations, Including New Analyses From ALKS 2680 Phase 1 Study – – New Research Evaluating the Clinical, Economic and Humanistic Burden of Narcolepsy and Findings From In-Depth Qualitative Patient Interviews on the Burden of Idiopathic Hypersomnia Will Also Be Presented – DUBLIN, May 29, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced plans to present new research related to ALKS 2680 at SLEEP 2025, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 8-11, 2025 in Seattle. ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 developm

      5/29/25 7:24:00 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alkermes Plc upgraded by UBS with a new price target

      UBS upgraded Alkermes Plc from Neutral to Buy and set a new price target of $42.00

      6/17/25 7:46:56 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Alkermes Plc with a new price target

      Needham initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $45.00

      5/28/25 8:55:31 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Alkermes Plc with a new price target

      RBC Capital Mkts initiated coverage of Alkermes Plc with a rating of Sector Perform and set a new price target of $40.00

      3/13/25 7:24:22 AM ET
      $ALKS
      Biotechnology: Pharmaceutical Preparations
      Health Care